Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 5.6% – What’s Next?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)’s share price fell 5.6% during trading on Tuesday . The company traded as low as $3.18 and last traded at $3.1330. 174,614 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 2,572,239 shares. The stock had previously closed at $3.32.

Analysts Set New Price Targets

A number of analysts recently commented on IRWD shares. Weiss Ratings reissued a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a report on Monday. Zacks Research downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Wells Fargo & Company boosted their target price on Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Finally, Wall Street Zen raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 9th. One equities research analyst has rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $5.34.

Ironwood Pharmaceuticals Price Performance

The company has a 50-day moving average of $1.99 and a two-hundred day moving average of $1.25. The stock has a market capitalization of $627.94 million, a PE ratio of -77.18 and a beta of 0.37.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Monday, November 10th. The biotechnology company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.09 by $0.15. The firm had revenue of $122.06 million during the quarter, compared to analyst estimates of $74.22 million. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current fiscal year.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Integrated Wealth Concepts LLC increased its holdings in Ironwood Pharmaceuticals by 21.4% in the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 3,406 shares during the last quarter. Merit Financial Group LLC lifted its stake in Ironwood Pharmaceuticals by 17.4% during the third quarter. Merit Financial Group LLC now owns 48,879 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 7,232 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Ironwood Pharmaceuticals by 3.5% during the third quarter. Rhumbline Advisers now owns 223,229 shares of the biotechnology company’s stock worth $292,000 after purchasing an additional 7,611 shares during the period. Focus Partners Wealth lifted its holdings in Ironwood Pharmaceuticals by 29.3% in the third quarter. Focus Partners Wealth now owns 44,652 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 10,105 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in Ironwood Pharmaceuticals by 83.2% in the third quarter. BNP Paribas Financial Markets now owns 34,331 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 15,594 shares during the period.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.